These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25327732)

  • 1. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
    Fu Y; Mi W; Li L; Zhang H; Wang J; Cheng W; Sun L; Li L; Xie S; Zhang J
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):506-9. PubMed ID: 25327732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Lopez LM; Kaptein AA; Helmerhorst FM
    Cochrane Database Syst Rev; 2012 Feb; (2):CD006586. PubMed ID: 22336820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
    Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
    Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
    Fenton C; Wellington K; Moen MD; Robinson DM
    Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
    Freeman EW; Kroll R; Rapkin A; Pearlstein T; Brown C; Parsey K; Zhang P; Patel H; Foegh M;
    J Womens Health Gend Based Med; 2001; 10(6):561-9. PubMed ID: 11559453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Lopez LM; Kaptein A; Helmerhorst FM
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006586. PubMed ID: 18254106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
    Freeman EW
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Lopez LM; Kaptein AA; Helmerhorst FM
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006586. PubMed ID: 19370644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
    Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
    Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Niknian M; Shulman LP; Lynen R
    Contraception; 2011 Jul; 84(1):81-6. PubMed ID: 21664515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.
    Guang-Sheng F; Mei-Lu B; Li-Nan C; Xiao-Ming C; Zi-Rong H; Zi-Yan H; Xiao-Ping J; Jian L; Shu-Ying W; Cheng-Liang X; Zheng-Ai X; Tian-Fu Y
    Clin Drug Investig; 2010; 30(6):387-96. PubMed ID: 20201608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder.
    Marr J; Heinemann K; Kunz M; Rapkin A
    Int J Gynaecol Obstet; 2011 May; 113(2):103-7. PubMed ID: 21338987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Ma S; Song SJ
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD006586. PubMed ID: 37365881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    J Drugs Dermatol; 2009 Sep; 8(9):837-44. PubMed ID: 19746676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Premenstrual Breakthrough of Depression With Adjunctive Oral Contraceptive Pills Compared With Placebo.
    Peters W; Freeman MP; Kim S; Cohen LS; Joffe H
    J Clin Psychopharmacol; 2017 Oct; 37(5):609-614. PubMed ID: 28816924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drospirenone/ethinyl estradiol.
    Rapkin AJ; Sorger SN; Winer SA
    Drugs Today (Barc); 2008 Feb; 44(2):133-45. PubMed ID: 18389090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice].
    Svojanovská K
    Ceska Gynekol; 2010 Oct; 75(5):474-80. PubMed ID: 21374928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
    Palli MB; Reyes-Habito CM; Lima XT; Kimball AB
    J Drugs Dermatol; 2013 Jun; 12(6):633-7. PubMed ID: 23839178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
    Lucky AW; Koltun W; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Cutis; 2008 Aug; 82(2):143-50. PubMed ID: 18792547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome.
    Freeman EW; Halbreich U; Grubb GS; Rapkin AJ; Skouby SO; Smith L; Mirkin S; Constantine GD
    Contraception; 2012 May; 85(5):437-45. PubMed ID: 22152588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.